Multiple Sclerosis

CLINICAL_TRIALS trial_result · 2008-12-19

Clinical Trial Update: BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients [Phase 3]

Phase 3 trial update reporting outcomes of a new dose of Betaferon/Betaseron (interferon beta-1b) in relapsing-remitting multiple sclerosis.…

CLINICAL_TRIALS trial_result · 2008-11-04

Clinical Trial Update: Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis [Phase 2]

Phase 2 trial of AV650 for spasticity in people with multiple sclerosis was terminated; the update discusses safety and preliminary effectiv…

CLINICAL_TRIALS research · 2008-10-17

Clinical Trial Update: Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study [NA]

This is a completed case study evaluating whole body vibration therapy for balance deficits in a participant with multiple sclerosis. The re…

CLINICAL_TRIALS trial_result · 2008-09-09

Clinical Trial Update: Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis [Phase 3]

Phase III randomized, double-blind, placebo-controlled trial evaluating intravenous immunoglobulin for multiple sclerosis has completed. The…

FDA approval · 2008-09-08

FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

FDA approved a supplemental application for Betaseron (interferon beta-1b) from Bayer HealthCare Pharmaceuticals, resulting in an approved m…

FDA approval · 2008-08-25

FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)

The FDA approved Biogen's supplemental application for TYSABRI (natalizumab), updating its labeling and/or indication.

FDA approval · 2008-08-13

FDA Approved: BACLOFEN — Supplemental Application (Chartwell RX, LLC)

FDA approved a supplemental application for baclofen submitted by Chartwell RX, LLC under ANDA 077241.

FDA approval · 2008-08-12

FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)

The FDA approved Biogen's supplemental application for TYSABRI (natalizumab).

CLINICAL_TRIALS trial_result · 2008-08-12

Clinical Trial Update: Multiple Sclerosis and Heavy Progressive Resistance Training [NA]

A clinical trial studying heavy progressive resistance training for individuals with Multiple Sclerosis has completed. The record lists the …

CLINICAL_TRIALS trial_result · 2008-08-05

Clinical Trial Update: Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis [Phase 2]

This clinical trial update reports the completion of a Phase 2 study evaluating subcutaneous daclizumab in patients with active, relapsing f…

CLINICAL_TRIALS trial_result · 2008-06-11

Clinical Trial Update: Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS) [Phase 1]

Phase 1 trial of constraint-induced movement therapy for progressive multiple sclerosis has completed. The study investigates CI therapy to …

CLINICAL_TRIALS trial_result · 2008-06-04

Clinical Trial Update: Auditory Function in Patients With and Without Multiple Sclerosis [Phase 2]

A Phase 2 clinical trial evaluating auditory function in patients with and without Multiple Sclerosis has completed.

CLINICAL_TRIALS trial_result · 2008-05-28

Clinical Trial Update: A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis [Phase 2]

Phase 2 clinical trial update for C105 assessing cognitive dysfunction in persons with multiple sclerosis; the study has completed.

CLINICAL_TRIALS research · 2008-05-19

Clinical Trial Update: A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone [Phase 3]

This clinical trial update describes a randomized, placebo-controlled, crossover Phase 3 study evaluating low-dose naltrexone in individuals…

CLINICAL_TRIALS trial_result · 2008-04-07

Clinical Trial Update: Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis [Phase 1]

A Phase 1 trial assessing immunotherapy BHT-3009 alone or combined with atorvastatin in patients with multiple sclerosis has completed.

FDA approval · 2008-04-02

FDA Approved: TIZANIDINE — Supplemental Application (Apotex Corp.)

The FDA approved a supplemental application from Apotex Corp. to market a generic version of tizanidine.

CLINICAL_TRIALS trial_result · 2008-03-28

Clinical Trial Update: Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis [Phase 1, Phase 2]

This document reports the completion of a Phase 1/2 safety trial of high-dose oral vitamin D3 with calcium in people with Multiple Sclerosis…

CLINICAL_TRIALS trial_result · 2008-03-21

Clinical Trial Update: Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS) [Phase 2]

A Phase 2 clinical trial evaluating NBI-5788, an altered peptide ligand, in relapsing multiple sclerosis has completed.

CLINICAL_TRIALS trial_result · 2008-03-05

Clinical Trial Update: EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis [Phase 4]

Phase 4 trial of early interferon beta-1a in combination with simvastatin for Clinically Isolated Syndrome suggestive of Multiple Sclerosis …